Miyakojima IGRT Clinic, 1-16-22 Miyakojimahondori, Miyakojima-ku, Osaka, 534-0021, Japan.
Department of Radiation Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Clin Transl Oncol. 2021 Feb;23(2):229-239. doi: 10.1007/s12094-020-02410-x. Epub 2020 Jun 5.
This study sought to discern the clinical outcomes of intensity-modulated radiation therapy (IMRT) administered to the spine in patients who had undergone previous radiotherapy.
A total of 81 sites of 74 patients who underwent previous radiotherapy administered to the spine or peri-spine and subsequently received IMRT for the spine were analyzed in this study. The prescribed dose of 80 Gy in a biologically effective dose (BED) of α/β = 10 (BED) was set as the planning target volume. The constraint for the spinal cord and cauda equine was D ≤ 100 Gy and ≤ 150 Gy of BED for re-irradiation alone and the total irradiation dose, respectively.
The median follow-up period was 10.1 (0.9-92.1) months after re-irradiation, while the median interval from the last day of the previous radiotherapy to the time of re-irradiation was 15.6 (0.4-210.1) months. Separately, the median prescript dose of re-irradiation was 78.0 (28.0-104.9) of BED. The median survival time in this study was 13.9 months, with 1-, 3-, and 5-year overall survival rates of 53.7%, 29.3%, and 26.6%, respectively. The 1-, 3-, and 5-year local control rates were 90.8%, 84.0%, and 84.0%, respectively. Neurotoxicity was observed in two of 72 treatments (2.8%) assessed after re-irradiation.
Re-irradiation for the spine using IMRT seems well-tolerated. Definitive re-irradiation can be a feasible treatment option in patients with the potential for a good prognosis.
本研究旨在探讨既往接受过脊柱或脊柱旁放射治疗的患者接受调强放疗(IMRT)治疗的临床结果。
本研究共分析了 74 例患者的 81 个部位,这些患者既往曾接受过脊柱或脊柱旁放疗,随后接受了脊柱 IMRT 治疗。将 80Gy 的生物有效剂量(BED)α/β=10(BED)设定为计划靶区剂量。对于单独再照射和总照射剂量,脊髓和马尾的限制分别为 D≤100Gy 和≤150Gy 的 BED。
再照射后中位随访时间为 10.1(0.9-92.1)个月,上次放疗结束至再照射时间的中位间隔为 15.6(0.4-210.1)个月。此外,再照射的中位处方剂量为 78.0(28.0-104.9)BED。本研究的中位生存时间为 13.9 个月,1、3 和 5 年总生存率分别为 53.7%、29.3%和 26.6%。1、3 和 5 年局部控制率分别为 90.8%、84.0%和 84.0%。再照射后评估的 72 例治疗中有 2 例(2.8%)出现神经毒性。
使用 IMRT 对脊柱进行再照射似乎可以耐受。对于有良好预后可能的患者,确定性再照射可能是一种可行的治疗选择。